Anti-osteoporotics(Roussel-Uclaf)(Anti-osteoporotics(Roussel-Uclaf))

概要

基本信息

药物类型

小分子化药

别名

anti-osteoporotics(Roussel-Uclaf)

靶点

ER

作用方式

激动剂

作用机制

ERs激动剂(雌激素受体家族激动剂)

治疗领域

内分泌与代谢疾病皮肤和肌肉骨骼疾病

在研适应症-

非在研适应症

骨质疏松症

原研机构

Aventis Pharma Japan

在研机构-

非在研机构

ImmunityBio, Inc.

权益机构-

最高研发阶段无进展药物发现

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 Anti-osteoporotics(Roussel-Uclaf) 相关的临床结果

登录后查看更多信息

100 项与 Anti-osteoporotics(Roussel-Uclaf) 相关的转化医学

登录后查看更多信息

100 项与 Anti-osteoporotics(Roussel-Uclaf) 相关的专利（医药）

登录后查看更多信息

15

项与 Anti-osteoporotics(Roussel-Uclaf) 相关的文献（医药）

2025-09-23·Endocrine Connections

Prevalence and risk factors of eligibility for anti-osteoporosis medication in a cohort of men ≥50 years and postmenopausal women who had already experienced bariatric surgery

Article

作者: Pattou, François ; Flament, Thomas ; Mortain, Léa ; Verkindt, Hélène ; Paccou, Julien

The 2022 recommendations of the European Calcified Tissue Society (ECTS) suggest initiating anti-osteoporotic medication (AOM) in case of a T-score ≤ −2 and/or in case of a fragility fracture within less than 2 years. Therefore, this study aimed to evaluate the eligibility for AOM in a cohort of patients referred for bone health assessment after bariatric surgery. This observational, cross-sectional, and monocentric study conducted at Lille University Hospital evaluated the prevalence of AOM eligibility according to the ECTS criteria in postmenopausal women and men aged ≥50 years referred for bone health assessment after bariatric surgery, either Roux-en-Y gastric bypass or sleeve gastrectomy, at least 2 years after bariatric surgery. Between June 2019 and June 2023, all participants were referred for bone health assessment, including systematic screening using dual-energy X-ray (DXA) and a standardized questionnaire by a radiology technician. Data between June 2023 and May 2024 were retrospectively reviewed. Among 140 patients (120 women, with an average age of 59 (55–63) years) seen for bone health assessment between June 2019 and June 2023, 33 met the ECTS guidelines for AOM, indicating a prevalence of 24% (CI 95%: 17–31%). Most patients met the BMD T-score ≤ −2 criterion ( n = 26/140, 19% (CI 95%: 12–25%)) and/or had a recent fragility fracture history ( n = 14/140, 10% (CI 95%: 5–15%)). In this study, one-fourth of the participants were eligible for AOM according to the ECTS guidelines.

2023-10-01·European journal of clinical pharmacology

Influence of non-osteoporotic treatments in patients on active anti-osteoporotic therapy: evidence from the OSTEOMED registry.

Article

作者: Arranz-García, Francisca ; Olmos, José Manuel ; Sosa-Henríquez, Manuel ; Amérigo, María José ; Pérez-Castrillón, José Luis ; Filgueira-Rubio, José ; Ruiz-Mambrilla, Marta ; Blázquez-Cabrera, José Antonio ; Navarro, Amalia ; Moro, María Jesús ; Díaz-Curiel, Manuel ; Montoya, María José ; Vázquez, María Ángeles ; Coco-Martín, María Begoña ; Leal-Vega, Luis

PURPOSE:

To evaluate the effect of different non-osteoporotic drugs on the increase or decrease in the risk of incident fragility fractures (vertebral, humerus or hip) in a cohort of patients diagnosed with osteoporosis on active anti-osteoporotic therapy.

METHODS:

For this retrospective longitudinal study, baseline and follow-up data on prescribed non-osteoporotic treatments and the occurrence of vertebral, humerus or hip fractures in 993 patients from the OSTEOMED registry were analyzed using logistic regression models. The drugs evaluated with a possible beneficial effect were thiazides and statins, while the drugs evaluated with a possible harmful effect were antiandrogens, aromatase inhibitors, proton pump inhibitors, selective serotonin reuptake inhibitors, benzodiazepines, GnRH agonists, thyroid hormones, and oral and inhaled corticosteroids.

RESULTS:

Logistic regression analyses indicated that no treatment significantly improved fracture risk, with the only treatments that significantly worsened fracture risk being letrozole (OR = 0.18, p-value = 0.03) and oral corticosteroids at doses ≤ 5 mg/day (OR = 0.16, p-value = 0.03) and > 5 mg/day (OR = 0.27, p-value = 0.04).

CONCLUSION:

The potential beneficial or detrimental effects of the different drugs evaluated on fracture risk are masked by treatment with anabolic or antiresorptive drugs that have a more potent action on bone metabolism, with two exceptions: letrozole and oral corticosteroids. These findings may have important clinical implications, as patients receiving these treatments are not fully protected by bisphosphonates, which may imply the need for more potent anti-osteoporotic drugs such as denosumab or teriparatide.

2022-12-01·Archives of osteoporosis3区 · 医学

Screening and management of osteoporosis: a survey of knowledge, attitude and practice among primary care physicians in Malaysia

3区 · 医学

Article

作者: Hussin, Narwani ; Lim, Wan Chieh ; Tay, Chai Li ; Ng, Wei Leik ; Beh, Hooi Chin

INTRODUCTION:

Prevention of osteoporotic fracture is important in primary healthcare for healthy ageing. Little is known about the knowledge, attitude, practice and barriers in the screening and managing osteoporosis among primary care doctors.

METHODS:

A cross-sectional study, using an online pre-tested questionnaire after face and content validation, was conducted for primary care doctors from 1 June to 30 July 2021 across Malaysia. Pearson's chi-square test and logistic regression were employed.

RESULTS:

A total of 350 primary care doctors in Malaysia, consisting of 113 (32.3%) family medicine specialists (FMS) and 237 (67.7%) medical officers, participated in this study. The mean ± SD score of osteoporosis knowledge was 50.46 ± 15.09 with minimum and maximum values of 0 and 83.64%, respectively. One hundred and ten (31.4%) respondents achieved a satisfactory overall knowledge score of ≥ 60%, 156 (44.6%) were confident in advising patients for initiation of anti-osteoporotic medication, and 243 (69.4%) perceived that bisphosphonate should be made available in health clinics. Only 97 (27.7%) practised osteoporosis screening. Inaccessibility of bone mineral densitometry (BMD) (90.6%), inadequate knowledge (87.7%) and inaccessibility of pharmacotherapy (87.1%) are perceived modifiable barriers to osteoporosis screening and management. Factors associated with a satisfactory knowledge of osteoporosis are designation as a family medicine specialist (AOR 3.034, p = 0.002), attendance at an osteoporosis management update course (AOR 2.095, p = 0.034) and the practice of osteoporosis screening for the elderly (AOR 2.767, p = 0.001).

CONCLUSION:

Given the insufficient knowledge and low level of osteoporosis screening, there is a need for a national structured health programme to address the knowledge gap, increase screening practices and enhance accessibility to BMD and anti-osteoporosis medication in primary care.

100 项与 Anti-osteoporotics(Roussel-Uclaf) 相关的药物交易

登录后查看更多信息